Compare Organon & Co. Common Stock (OGN) vs Workday Inc (WDAY) Price & Performance

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

Workday (WDAY) trades at $186.02, down 1.18% on the day, reflecting a recent market pullback amid broader tech sector volatility. The stock maintains a bullish technical signal with strong analyst consensus support, evidenced by 50.6% buy ratings and a $203.19 average price target. Recent earnings beats and a 200% YoY surge in AI Annual Recurring Revenue to $600 million highlight robust fundamental momentum, though net cash flow turned negative in 2025 due to strategic investments.

WDAY's outlook remains positive, driven by AI integration and expansion into new markets like the UAE, but risks include execution challenges from recent layoffs and heightened competition. The stock's premium valuation (P/E 37.89) requires sustained high growth to justify further upside, making earnings performance the critical near-term catalyst.